Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial Supplement 1. Supplement 2. Statistical analysis plan Supplement 3. eTable 1. Investigator and IRB/IEC Lists eTable 2. Reasons for screen failure and exclusion from randomization eTable 3. Laboratory reference values eFigure.
What Is New? The work reported here demonstrates the de novo invention of a novel macrocyclic peptide, MK-0616, capable of achieving the potency and selectivity of an antibody in a form that can be taken orally. This provides validation and guidance for the use of mRNA display technology, a major advancement in the medicinal chemistry underlying drug discovery. What Are the Clinical Implications?
Pay Per Article - You may access this article (from the computer you are currently using) for 2 days for US$25.00 Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
Cardiac magnetic resonance parameters associated with successful conversion from one to one-and-half or two ventricle circulation in patients with hypoplastic right ventricle Deepa Prasad, Andrew Powell, Sitaram E. Emani, Puja Banka Pediatrics May 2018, 142 (1 MeetingAbstract) 84; DOI: 10.1542/peds.142.1_MeetingAbstract.84
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
